Normally when you put out a product, you want to take sales away from the competition, not from other products that you sell yourself. But that's exactly what Gilead Sciences (NASDAQ:GILD) is doing, and Motley Fool health care analyst David Williamson thinks it's a great move.  Watch the video to find out why.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.